Literature DB >> 24046188

[Diagnosis of and therapy for choroidal melanoma].

A C Lipski1, N Lakotka, A I Riechardt, G D Willerding, J Heufelder, S Türkmen, U Keilholz, L Moser, A M Joussen.   

Abstract

BACKGROUND: Prognosis evaluation of patients with choroidal and ciliary melanoma has experienced recent progress through tumour sampling and cytogenetic analysis of metastatic risk. By allocating tumor extension, height and linear basal diameter to defined TNM stages, an estimation of prognosis can also be made without invasive tissue sampling.
METHODS: Therapeutic strategies of organ preserving irradiation using different sources have clearly come to the forefront.
RESULTS: Due to microscopic haematogenous spreading of tumour cells prior to treatment, the metastatic risk following radiation of any form is not influenced in comparison to primary enucleation.
CONCLUSION: However, metastatic disease still remains a fatal condition which currently may only be influenced by early detection and treatment of uveal melanomas. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 24046188     DOI: 10.1055/s-0033-1350833

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  3 in total

1.  Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy.

Authors:  Markus Wösle; Lothar Krause; Shanthala Sreenivasa; Dirk Vordermark; Ilja F Ciernik
Journal:  Strahlenther Onkol       Date:  2018-08-16       Impact factor: 3.621

Review 2.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

3.  [Immunotherapy of uveal melanoma: vaccination against cancer. Multicenter adjuvant phase 3 vaccination study using dendritic cells laden with tumor RNA for large newly diagnosed uveal melanoma].

Authors:  B Schuler-Thurner; K-U Bartz-Schmidt; N Bornfeld; C Cursiefen; B Fuisting; S Grisanti; L M Heindl; L Holbach; M Keserü; H Knorr; K Koch; F Kruse; R Meiller; C Metz; T Meyer-ter-Vehn; M Much; M Reinsberg; S Schliep; B Seitz; G Schuler; D Süsskind; A Viestenz; L Wagenfeld; M Zeschnigk
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.